ASX-listed PharmAust appears to have made a breakthrough in its fight to combat canine cancer with a “phase IIb” trial of its Monepantel anti-cancer drug reportedly achieving tumour regression and increased progression-free survival in dogs. The company says the results could have significant implications for human cancer treatment and it will now fast-track to phase-three animal trials.
28/06/2021 - 17:37
PharmAust delivers breakthrough in canine cancer fight
By Matt Birney
28/06/2021 - 17:37
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 142nd Hazer Group $2.4m 143rd Mustera Property Group $2.3m 145th RemSense Technologies $2.2m 146th BauMart Holdings $2.2m 203 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX